Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.37 USD | +0.06% | -1.77% | +31.07% |
Sales 2024 * | 52.9M 4.23B | Sales 2025 * | 67.47M 5.4B | Capitalization | 2.05B 164B |
---|---|---|---|---|---|
Net income 2024 * | -218M -17.45B | Net income 2025 * | -252M -20.17B | EV / Sales 2024 * | 28.9 x |
Net cash position 2024 * | 516M 41.34B | Net cash position 2025 * | 463M 37.05B | EV / Sales 2025 * | 23.5 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-9.48
x | Employees | 187 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | +0.06% | ||
1 week | -1.77% | ||
Current month | -16.99% | ||
1 month | -15.50% | ||
3 months | +7.58% | ||
6 months | +189.92% | ||
Current year | +31.07% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 31/08/15 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 14/07/19 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 04/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 03-27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 30/04/18 |
John Maraganore
BRD | Director/Board Member | 60 | 16/01/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 33.37 | +0.06% | 452,364 |
25/04/24 | 33.35 | -5.28% | 786,230 |
24/04/24 | 35.21 | -1.40% | 379,566 |
23/04/24 | 35.71 | +3.96% | 437,029 |
22/04/24 | 34.35 | +1.12% | 417,209 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.07% | 2.05B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- KYMR Stock